CoChat

Residual immune response towards decellularized homografts may be highly individual

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: Decellularized homograft valves (DHVs) have shown promising clinical results, particularly in the treatment of congenital heart disease. However, DHV appears to elicit an immune response in a subset of young patients, indicated by early valve degeneration. As the decellularization process is quality controlled for each DHV, we hypothesized that there may be residual immunogenicity within the extracellular matrix of DHV. METHODS: A semi-quantitative dot blot analysis was established to screen for preformed recipient antibodies using secondary anti-human antibodies. Fifteen DHV samples (7 aortic, 8 pulmonary) were solubilized and exposed to serum from 20 healthy controls. RESULTS: The sera from young controls (n = 10, 18–25 years) showed significantly stronger binding of preformed antibodies than sera from older individuals (n = 10, 48–73 years). The difference between the means of arbitrary units was 15.1 ± 6.5 (P = 0.0315). There was high intraindividual variance in the mean amounts of arbitrary units of antibody binding with some healthy controls showing >10 times higher antibody binding towards 2 different DHV. The amount of preformed antibodies bound to DHVs was higher in aortic than in pulmonary DHVs. The mean number of antibody binding (in arbitrary units) was 17.2 ± 4.5 in aortic and 14.5 ± 4.7 in pulmonary DHV (P = 0.27). The amount of preformed antibodies bound to pulmonary DHVs was statistically significantly higher in the sera of healthy males (n = 10) than in the sera of healthy females (n = 10). The mean number of arbitrary units was 17.2 ± 4.2 in male and 11.7 ± 5.3 in female sera (P = 0.036). Antibody binding to aortic DHV was also higher in males, but not significant (18.8 ± 5.0 vs 15.6 ± 4.0). Blood group (ABO) incompatibility between the serum from controls and DHV showed no impact on antibody binding, and there was no age-related impact among DHV donors. CONCLUSIONS: Residual immunogenicity of decellularized homografts appears to exist despite almost complete cell removal. The established dot blot method allows a semi-quantitative assessment of the individual immune response towards extracellular DHV components and potentially the possibility of preoperative homograft matching.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ejcts/ezaa393

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC BY-NC · PubMed Central
Figure 1: Overview—method to quantify the binding of preformed antibodies to decellularized homograft valve (A). Membrane loading: standards 1–6 and samples of pulmonary decellularized homograft valve (n = 8) (B). Regression of standards. Standards 1 and 2 are excluded because they were oversaturated at the chosen exposure time, which would artificially affect the regression line. A shorter exposure time would not be enough to display standards 5 and 6 (C). Amounts of arbitrary units of preformed antibodies bound to pulmonary decellularized homograft valve (n = 8) in a human serum. Negative values after baseline subtraction that arose in some cases can be explained by steric overlays between remaining donor antibodies and serum antibodies (D). DHV: decellularized homograft valve.
Figure 1: Overview—method to quantify the binding of preformed antibodies to decellularized homograft valve (A). Membrane loading: standards 1–6 and samples of pulmonary decellularized homograft valve (n = 8) (B). Regression of standards. Standards 1 and 2 are excluded because they were oversaturated at the chosen exposure time, which would artificially affect the regression line. A shorter exposure time would not be enough to display standards 5 and 6 (C). Amounts of arbitrary units of preformed antibodies bound to pulmonary decellularized homograft valve (n = 8) in a human serum. Negative values after baseline subtraction that arose in some cases can be explained by steric overlays between remaining donor antibodies and serum antibodies (D). DHV: decellularized homograft valve.CC BY-NC · PubMed Central
Figure 2: Examples for the binding of preformed antibodies in the serum of a young female (A) and an older male (B) to pulmonary decellularized homograft valve (n = 8) as well as the binding of preformed antibodies in the sera of a young male (C) and an older female (D) to aortic decellularized homograft valve (n = 7). DHV: decellularized homograft valve.
Figure 2: Examples for the binding of preformed antibodies in the serum of a young female (A) and an older male (B) to pulmonary decellularized homograft valve (n = 8) as well as the binding of preformed antibodies in the sera of a young male (C) and an older female (D) to aortic decellularized homograft valve (n = 7). DHV: decellularized homograft valve.CC BY-NC · PubMed Central
Figure 3: Mean amounts of arbitrary units of preformed antibodies bound to: (A) aortic and pulmonary decellularized homograft valve (n = 15) in the sera of male (n = 10) and female (n = 10) healthy subjects; (B) aortic and pulmonary decellularized homograft valve (n = 15) in the sera of young (n = 10) and old (n = 10) healthy subjects; (C) aortic (n = 7) and pulmonary (n = 8) decellularized homograft valve in the sera of 20 healthy subjects; (D) pulmonary decellularized homograft valve (n = 8) in the sera of male (n = 10) and female (n = 10) healthy subjects; and (E) aortic decellularized homograft valve (n = 7) in the sera of male (n = 10) and female (n = 10) healthy subjects. DHV: decellularized homograft valve.
Figure 3: Mean amounts of arbitrary units of preformed antibodies bound to: (A) aortic and pulmonary decellularized homograft valve (n = 15) in the sera of male (n = 10) and female (n = 10) healthy subjects; (B) aortic and pulmonary decellularized homograft valve (n = 15) in the sera of young (n = 10) and old (n = 10) healthy subjects; (C) aortic (n = 7) and pulmonary (n = 8) decellularized homograft valve in the sera of 20 healthy subjects; (D) pulmonary decellularized homograft valve (n = 8) in the sera of male (n = 10) and female (n = 10) healthy subjects; and (E) aortic decellularized homograft valve (n = 7) in the sera of male (n = 10) and female (n = 10) healthy subjects. DHV: decellularized homograft valve.CC BY-NC · PubMed Central
Figure 4: Graphical overview of preformed antibody binding according to age for healthy controls, showing less binding in older subjects (R2 linear = 0.150).
Figure 4: Graphical overview of preformed antibody binding according to age for healthy controls, showing less binding in older subjects (R2 linear = 0.150).CC BY-NC · PubMed Central
Figure 5: Preformed antibody binding differentiated by ABO compatibility between control serum and the decellularized homograft valve donor, showing no difference.
Figure 5: Preformed antibody binding differentiated by ABO compatibility between control serum and the decellularized homograft valve donor, showing no difference.CC BY-NC · PubMed Central
Figure 6: Graphical overview of preformed antibody binding according to decellularized homograft valve donor age, showing no correlation. DHV: decellularized homograft valve.
Figure 6: Graphical overview of preformed antibody binding according to decellularized homograft valve donor age, showing no correlation. DHV: decellularized homograft valve.CC BY-NC · PubMed Central
Figure 7: Graphical overview of inter-experimental variance and maximum differences in preformed antibody binding between specific decellularized homograft valve according to the age of healthy controls. DHV: decellularized homograft valve.
Figure 7: Graphical overview of inter-experimental variance and maximum differences in preformed antibody binding between specific decellularized homograft valve according to the age of healthy controls. DHV: decellularized homograft valve.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 30

Metadata

Authors
Ebken, J., Mester, N., Smart, I., Ramm, R., Goecke, T., Jashari, R., Böthig, D., Horke, A., Cebotari, S., Tudorache, I., Avsar, M., Bobylev, D., Haverich, A., Sarikouch, S., & Hilfiker, A.
Affiliations
  • Medizinische Hochschule Hannover (DE)
  • Clinique Saint Jean (BE)
Corresponding author
Sarikouch, Samir
Venue
European Journal of Cardio-Thoracic Surgery
Published
2020-12-03
Volume
59
Issue
4
Pages
773-782
ISSN
  • 1010-7940 (ISSN-L)
  • 1873-734X
OpenAlex
W3127211246
Cited by
29
References
32
Citations by year
2026: 4 · 2025: 6 · 2024: 5 · 2023: 7 · 2022: 6 · 2020: 1
FWCI
3.20
Type
journal article
Language
en
Open access
Locations
  • European Journal of Cardio-Thoracic Surgery (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
European Union’s HORIZON 2020 Programme (643597)
Topics
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Congenital Heart Disease Studies
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
Keywords
extracellular matrix, congenital heart disease, aortic valve replacement, pulmonary valve replacement, sex differences, ABO incompatibility, valve degeneration, xenotransplantation, immunosuppression
MeSH terms
Aortic Valve, Female, Heart Defects, Congenital, Humans, Immunity, Male, Pulmonary Valve, Transplantation, Homologous, Allografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.